Abivax S.A. (ABVX) Stock: Price, Forecast & Analyst Target
Abivax S.A. (ABVX) — MoonshotScore 53/100 (Fair band), calculated Nov 18, 2026. Price $73.20 (-9.24%), as of the Nov 20, 2026 trading session; market cap $6.41B. Expected results Dec 21, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Abivax S.A. · ABVX · NASDAQ · Healthcare · Biotechnology
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Abivax (ABVX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, but stalling growth and a full valuation. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.
- quarterly revenue €0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 0 of the last 4 reports
- Altman Z 36.47 · Piotroski F 3
Holding back: soft growth
Helping: business quality, balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 59 | Fair | |
| 52 | Fair | |
| 52 | Fair | |
| 53 | Fair | |
| 53 | Fair | |
| 53 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $73.20 | |
| Change on the day | -9.24% | |
| 52-week range | $69.81–$148.83 | |
| Market capitalisation | $6.41B | — |
| Shares traded on the day | 14.82M | |
| Beta (volatility vs the S&P 500) | -0.25 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Abivax (ABVX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Abivax (ABVX), and what does it report?
Short answer
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. Abivax S.A. (ABVX) is listed on NASDAQ. Abivax S.A. (ABVX) is classified as Healthcare / Biotechnology. SEC filing business address: 7 BD Haussmann, Paris. It employs 98 people and is led by Marc de Garidel. In Q2 FY2026 it reported revenue of €0 and net income of -€117M. The market values it at $6.41B.
What do the latest results show for Abivax (ABVX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of €0. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.37M Sep 21, 2026
- Latest report · revenue estimate
- $799,166 Sep 21, 2026
- Latest report · revenue vs estimate
- Above estimate Sep 21, 2026
- Latest report · EPS vs estimate
- Below estimate Sep 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Sep 21, 2026 | $1.37M | $799,166 | −$1.7100 | −$0.9755 |
| May 22, 2026 | $1.51M | $401,125 | −$0.7100 | −$1.0700 |
| Mar 23, 2026 | $515,064 | $1.80M | −$1.1900 | −$1.7000 |
| Dec 15, 2025 | $2.40M | $1.35M | −$2.4717 | −$0.7865 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | €0 | -€117M | -€1.47 (diluted) |
| Q4 FY2025 | €0 | -€288M | -€4.14 (diluted) |
| Q2 FY2025 | €0 | -€48M | -€0.76 (diluted) |
| Q4 FY2024 | €0 | -€52M | -€0.83 (diluted) |
What are the financial strengths and risks for Abivax (ABVX)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 36.47 · Piotroski F 3. Trailing ratios: ROA -57.5% · current ratio 8.75 · earnings yield -4.3% · free-cash-flow yield -1.8%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Abivax (ABVX)?
Short answer · as of
The next earnings report is expected on Dec 21, 2026. Current published price targets run low $118.00 · high $180.00 · consensus $156.00 · median $156.50 against a quoted price of $73.20 (as of Nov 20, 2026).
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Abivax compare with its peers?
Short answer
Abivax's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.89 Nov 20, 2026 | $7.38B | 98 5-pillar Nov 18, 2026 | |
| $308.89 Nov 20, 2026 | $9.15B | 96 5-pillar Nov 18, 2026 | |
| $63.62 Nov 20, 2026 | $6.96B | 91 5-pillar Nov 18, 2026 | |
| $121.40 Nov 20, 2026 | $7.92B | 88 5-pillar Nov 18, 2026 | |
| $39.91 Nov 20, 2026 | $4.37B | 84 5-pillar Nov 18, 2026 | |
| $17.58 Nov 20, 2026 | $5.04B | 83 5-pillar Nov 18, 2026 | |
| $286.85 Nov 20, 2026 | $5.74B | 71 5-pillar Nov 18, 2026 | |
| $95.81 Nov 20, 2026 | $6.50B | 67 5-pillar Nov 18, 2026 | |
| $13.61 Nov 20, 2026 | $4.78B | 67 5-pillar Nov 18, 2026 | |
| $119.52 Nov 20, 2026 | $5.04B | 66 5-pillar Nov 18, 2026 | |
| $127.38 Nov 20, 2026 | $5.17B | 64 5-pillar Nov 18, 2026 | |
| Abivax (ABVX) — this page | $73.20 | $6.41B | 53 |
| $236.45 Nov 19, 2026 | $15.2B | 40 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $118.00 – $180.00
- Consensus target
- $156.00
- Median target
- $156.50
Consensus record · Captured .
Measured against a quoted price of $73.20 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 71.7% Period end Sep 30, 2026
- Previous quarter · ownership
- 79.1% Prior to period end Sep 30, 2026
- Reporting holders
- 364 Period end Sep 30, 2026
- Previous quarter · holders
- 372 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Helikon Investments Ltd | 4,222,896 |
| Darwin Global Management, Ltd. | 4,021,583 |
| Vestal Point Capital, LP | 3,960,000 |
| Tcg Crossover Management, LLC | 3,663,038 |
| Citadel Advisors LLC | 2,171,400 |
Tracked investors
Which of the 16 named investors we follow held ABVX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ABVX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Abivax (ABVX)?
Abivax Healthcare Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ABVX research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ABVX?
ABVX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ABVX a good stock to buy?
Stock Expert AI does not rate ABVX buy, sell or hold. Abivax S.A. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ABVX stock price today?
The last price recorded for Abivax S.A. (ABVX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ABVX price target?
The analyst consensus price target for Abivax S.A. (ABVX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for ABVX?
The primary risks for Abivax S.A. stem from the inherent uncertainties of drug development. These include the potential for clinical trial failures at any stage, which could significantly impede product development and market prospects.
What are the key factors to evaluate for ABVX?
Abivax S.A. (ABVX) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Engages in early-stage research programs for infectious diseases such as Dengue fever, influenza, and respiratory syncytial virus. Not financial advice.
How frequently does ABVX data refresh on this page?
ABVX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ABVX's recent stock price performance?
Abivax S.A. (ABVX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ABVX overvalued or undervalued right now?
Abivax S.A. (ABVX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 52 figures on this page — 1 from SEC filings and earnings calls, 44 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com